Tapinarof Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated: May 26, 2026

The clinical evidence base for Tapinarof comprises 25 peer-reviewed publications across 15 journals, 44 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Dermatitis, Atopic, and Psoriasis. Most recent publication: Tapinarof Improved Outcomes and Sleep for Patients and Families in Two Phase 3 Atopic Dermatitis Trials in Adults and Children., Dermatol Ther (Heidelb), 2025.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials.
Silverberg JI, Eichenfield LF, Hebert AA, et al. · J Am Acad Dermatol · 2024
PubMed: PMID 38777187 · NCT05032859 · Dermatitis, Atopic
Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis.
Lebwohl MG, Stein Gold L, Strober B, et al. · N Engl J Med · 2021
PubMed: PMID 34879448 · NCT03956355 · Psoriasis
Tapinarof Cream 1% for Extensive Plaque Psoriasis: A Maximal Use Trial on Safety, Tolerability, and Pharmacokinetics.
Jett JE, McLaughlin M, Lee MS, et al. · Am J Clin Dermatol · 2022
PubMed: PMID 34713415 · NCT04042103
Tapinarof Improved Outcomes and Sleep for Patients and Families in Two Phase 3 Atopic Dermatitis Trials in Adults and Children.
Simpson EL, Hebert AA, Browning J, et al. · Dermatol Ther (Heidelb) · 2025
PubMed: PMID 39777610 · NCT05014568 · Dermatitis, Atopic
Maximal Usage Trial of Tapinarof Cream 1% Once Daily in Pediatric Patients Down to 2 Years of Age with Extensive Atopic Dermatitis.
Paller AS, Hebert AA, Gonzalez ME, et al. · Am J Clin Dermatol · 2025
PubMed: PMID 40126804 · NCT05186805 · Dermatitis, Atopic
Tapinarof cream 1% once daily was well tolerated in adults and children with atopic dermatitis in two phase 3 randomized trials.
Gold LS, Del Rosso J, Ehst BD, et al. · J Dermatolog Treat · 2025
PubMed: PMID 39799945 · NCT05032859 · Dermatitis, Atopic
Characteristics and management of follicular events and contact dermatitis in patients using tapinarof cream for the treatment of atopic dermatitis or plaque psoriasis.
Gold LS, Bruno MJ, Lewitt GM, et al. · J Dermatolog Treat · 2025
PubMed: PMID 40600584 · NCT05014568 · Dermatitis, Atopic
Tapinarof Cream for Adults and Children with Atopic Dermatitis-Efficacy by Race and Fitzpatrick Skin Type in Two Phase 3 Randomized Clinical Trials.
Alexis AF, Kircik L, Chovatiya R, et al. · Dermatol Ther (Heidelb) · 2025
PubMed: PMID 40696240 · NCT05014568 · Dermatitis, Atopic

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

Trial	Indication	Primary endpoint	Arm	Value
NCT03956355	Psoriasis	Percent of Subjects Who Achieve a Physician Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) With a Minimum 2-grade Improvement From Baseline at Week 12. Analyses Were Done Using Multiple Imputation Baseline to Week 12	Tapinarof (DMVT-505)	35.4 percentage of subjects (±2.75 Standard Error)
NCT03956355	Psoriasis		Vehicle Cream	6.0 percentage of subjects (±2.08 Standard Error)
NCT03983980	Psoriasis	Percent of Subjects Who Achieve a Physician Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) With a Minimum 2-grade Improvement From Baseline at Week 12. Analyses Were Done Using Multiple Imputation Baseline to Week 12	Tapinarof (DMVT-505) Cream Group	40.2 percentage of subjects (±2.82 Standard Error)
NCT03983980	Psoriasis		Vehicle Cream Group	6.3 percentage of subjects (±1.99 Standard Error)
NCT04053387	Psoriasis	Change From Baseline in %BSA Affected Baseline to 40 weeks	Continuous or Intermittent Use of Tapinarof (DMVT-505) Cream According to PGA Score	-2.03 percentage of BSA affected (±4.848 Standard Deviation)
NCT04053387	Psoriasis	Change From Baseline in Disease Impact on Daily Activities, as Measured by the Dermatology Life Quality Index (DLQI) Baseline to 40 weeks	Continuous or Intermittent Use of Tapinarof (DMVT-505) Cream According to PGA Score	-2.0 scores on a scale (±4.31 Standard Deviation)
NCT04053387	Psoriasis	Change From Baseline in Psoriasis Area and Severity Index (PASI) Score Baseline to 40 weeks	Continuous or Intermittent Use of Tapinarof (DMVT-505) Cream According to PGA Score	-1.80 scores on a scale (±4.334 Standard Deviation)
NCT04053387	Psoriasis	Complete Disease Clearance During LTE: Number of Subjects Achieving Disease Clearance PGA =0 (Clear) While on Therapy for Subjects Entered LTE PGA ≥ 1 (Almost Clear) Baseline to 44 weeks	Continuous or Intermittent Use of Tapinarof (DMVT-505) Cream According to PGA Score	233 Participants
NCT04053387	Psoriasis	Frequency of Adverse Events and Serious Adverse Events Baseline to 44 weeks	Continuous or Intermittent Use of Tapinarof (DMVT-505) Cream According to PGA Score	21 events
NCT04053387	Psoriasis		Continuous or Intermittent Use of Tapinarof (DMVT-505) Cream According to PGA Score	1190 events
NCT04053387	Psoriasis	Mean Duration (Days) of Treatment Course Baseline to 40 weeks	Continuous or Intermittent Use of Tapinarof (DMVT-505) Cream According to PGA Score	172.9 days (±102.17 Standard Deviation)
NCT04053387	Psoriasis	Number of Subjects With Adverse Events and Serious Adverse Events Baseline to 44 weeks	Continuous or Intermittent Use of Tapinarof (DMVT-505) Cream According to PGA Score	19 Participants
NCT04053387	Psoriasis		Continuous or Intermittent Use of Tapinarof (DMVT-505) Cream According to PGA Score	474 Participants
NCT04053387	Psoriasis	Number of Subjects With Clinically Meaningful Changes From Baseline in Clinical Laboratory Values and Vital Signs Baseline to 40 weeks	Continuous or Intermittent Use of Tapinarof (DMVT-505) Cream According to PGA Score	7 Participants
			Continuous or Intermittent Use of Tapinarof (DMVT-505) Cream According to PGA Score	0 Participants
			Continuous or Intermittent Use of Tapinarof (DMVT-505) Cream According to PGA Score	0 Participants
			Continuous or Intermittent Use of Tapinarof (DMVT-505) Cream According to PGA Score	0 Participants
			Continuous or Intermittent Use of Tapinarof (DMVT-505) Cream According to PGA Score	6 Participants
			Continuous or Intermittent Use of Tapinarof (DMVT-505) Cream According to PGA Score	16 Participants
NCT04053387	Psoriasis	Percent Change From Baseline in %BSA Affected Baseline to 40 weeks	Continuous or Intermittent Use of Tapinarof (DMVT-505) Cream According to PGA Score	-18.48 percentage change (±149.908 Standard Deviation)
NCT04053387	Psoriasis	Percent Change From Baseline in Disease Impact on Daily Activities, as Measured by the Dermatology Life Quality Index (DLQI) Baseline to 40 weeks	Continuous or Intermittent Use of Tapinarof (DMVT-505) Cream According to PGA Score	-37.1 percentage change (±121.35 Standard Deviation)
NCT04053387	Psoriasis	Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score Baseline to 40 weeks	Continuous or Intermittent Use of Tapinarof (DMVT-505) Cream According to PGA Score	-11.90 percentage change (±151.684 Standard Deviation)
NCT04053387	Psoriasis	Remittive Effect of Treatment Success in Pivotal: Median Time to First Worsening (PGA ≥ 2) While Off Therapy for Subjects Who Entered LTE PGA = 0 (Clear) Baseline to 44 weeks	Continuous or Intermittent Use of Tapinarof (DMVT-505) Cream According to PGA Score	115 days from baseline visit
NCT04053387	Psoriasis	Remittive Effect of Treatment Success: Number of Subjects Experiencing Worsening (PGA ≥ 2) While Off Therapy for Subjects Who Entered LTE With a PGA = 0 (Clear) Baseline to 44 weeks	Continuous or Intermittent Use of Tapinarof (DMVT-505) Cream According to PGA Score	19 Participants
NCT04053387	Psoriasis		Continuous or Intermittent Use of Tapinarof (DMVT-505) Cream According to PGA Score	60 Participants
NCT04053387	Psoriasis	Response During LTE: Number of Subjects Achieving PGA =0 or 1 (Clear or Almost Clear) While on Therapy for Subjects Who Entered LTE With PGA ≥ 2 (Mild) Baseline to 44 weeks	Continuous or Intermittent Use of Tapinarof (DMVT-505) Cream According to PGA Score	302 Participants
NCT05014568	Dermatitis, Atopic	Percent of Subjects Who Have a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Score of Clear or Almost Clear (0 or 1) With a Minimum 2-grade Improvement From Baseline to Week 8. Analyses Were Done Using Multiple Imputation. Baseline to Week 8	Tapinarof Cream	45.4 Percentage of participants
NCT05014568	Dermatitis, Atopic		Vehicle Cream	13.9 Percentage of participants
NCT05032859	Dermatitis, Atopic	Percent of Subjects Who Have a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Score of Clear or Almost Clear (0 or 1) With a Minimum 2-grade Improvement From Baseline to Week 8. Analyses Were Done Using Multiple Imputation. Baseline to Week 8	Tapinarof Cream	46.4 Percentage of participants
NCT05032859	Dermatitis, Atopic		Vehicle Cream	18.0 Percentage of participants
NCT05142774	Dermatitis, Atopic	Absolute Change From Baseline in %BSA Affected Baseline to Week 48	Tapinarof Cream	-7.14 percentage of BSA (±12.881 Standard Deviation)
NCT05142774	Dermatitis, Atopic	Change From Baseline in Clinical Laboratory Values (%) Baseline to Week 48	Tapinarof Cream	-0.73 % of cells (±10.440 Standard Deviation)
			Tapinarof Cream	-0.06 % of cells (±0.402 Standard Deviation)
			Tapinarof Cream	-0.39 % of cells (±3.427 Standard Deviation)
			Tapinarof Cream	0.03 % of cells (±0.272 Standard Deviation)
			Tapinarof Cream	1.18 % of cells (±11.436 Standard Deviation)
			Tapinarof Cream	-0.09 % of cells (±2.592 Standard Deviation)
NCT05142774	Dermatitis, Atopic	Change From Baseline in Clinical Laboratory Values (10^12 Cells/L) Baseline to Week 48	Tapinarof Cream	0.038 10^12 cells/L (±0.2905 Standard Deviation)
NCT05142774	Dermatitis, Atopic	Change From Baseline in Clinical Laboratory Values (10^9 Cells/L) Baseline to Week 48	Tapinarof Cream	0.01 10^9 cells/L (±0.051 Standard Deviation)
			Tapinarof Cream	-0.02 10^9 cells/L (±0.909 Standard Deviation)
			Tapinarof Cream	0.00 10^9 cells/L (±0.192 Standard Deviation)
			Tapinarof Cream	-4.0 10^9 cells/L (±59.57 Standard Deviation)
			Tapinarof Cream	0.18 10^9 cells/L (±2.474 Standard Deviation)
			Tapinarof Cream	-.03 10^9 cells/L (±0.308 Standard Deviation)
			Tapinarof Cream	0.22 10^9 cells/L (±2.079 Standard Deviation)
NCT05142774	Dermatitis, Atopic	Change From Baseline in Clinical Laboratory Values (fl) Baseline to Week 48	Tapinarof Cream	0.37 fl (±2.364 Standard Deviation)
NCT05142774	Dermatitis, Atopic	Change From Baseline in Clinical Laboratory Values (g/L) Baseline to Week 48	Tapinarof Cream	0.0 g/L (±3.95 Standard Deviation)
			Tapinarof Cream	-0.5 g/L (±2.43 Standard Deviation)
			Tapinarof Cream	1.7 g/L (±8.45 Standard Deviation)
			Tapinarof Cream	0.0 g/L (±7.61 Standard Deviation)
NCT05142774	Dermatitis, Atopic	Change From Baseline in Clinical Laboratory Values (L/L) Baseline to Week 48	Tapinarof Cream	0.005 L/L (±0.0263 Standard Deviation)
NCT05142774	Dermatitis, Atopic	Change From Baseline in Clinical Laboratory Values (mmol/L) Baseline to Week 48	Tapinarof Cream	-0.03 mmol/L (±0.493 Standard Deviation)
			Tapinarof Cream	-0.2 mmol/L (±2.31 Standard Deviation)
			Tapinarof Cream	0.04 mmol/L (±1.428 Standard Deviation)
			Tapinarof Cream	0.13 mmol/L (±1.462 Standard Deviation)
			Tapinarof Cream	-0.1 mmol/L (±2.14 Standard Deviation)
			Tapinarof Cream	-0.019 mmol/L (±0.0926 Standard Deviation)
			Tapinarof Cream	-0.3 mmol/L (±2.43 Standard Deviation)
NCT05142774	Dermatitis, Atopic	Change From Baseline in Clinical Laboratory Values (pg) Baseline to Week 48	Tapinarof Cream	0.13 pg (±0.823 Standard Deviation)
NCT05142774	Dermatitis, Atopic	Change From Baseline in Clinical Laboratory Values (U/L) Baseline to Week 48	Tapinarof Cream	-14.9 U/L (±69.45 Standard Deviation)
			Tapinarof Cream	-2.6 U/L (±16.13 Standard Deviation)
			Tapinarof Cream	-1.5 U/L (±11.96 Standard Deviation)
NCT05142774	Dermatitis, Atopic	Change From Baseline in Clinical Laboratory Values (Umol/L) Baseline to Week 48	Tapinarof Cream	2.7 umol/L (±12.06 Standard Deviation)
			Tapinarof Cream	2.1 umol/L (±7.92 Standard Deviation)
			Tapinarof Cream	0.40 umol/L (±3.434 Standard Deviation)
			Tapinarof Cream	0.9 umol/L (±52.32 Standard Deviation)
NCT05142774	Dermatitis, Atopic	Change From Baseline in Vital Signs - Blood Pressure (Systolic and Diastolic) Baseline to Week 48	Tapinarof Cream	1.0 mmHg (±10.72 Standard Deviation)
NCT05142774	Dermatitis, Atopic		Tapinarof Cream	0.7 mmHg (±9.78 Standard Deviation)
NCT05142774	Dermatitis, Atopic	Change From Baseline in Vital Signs - Pulse Baseline to Week 48	Tapinarof Cream	-0.9 beats per minute (bpm) (±12.61 Standard Deviation)
NCT05142774	Dermatitis, Atopic	Change From Baseline in Vital Signs - Temperature Baseline to Week 48	Tapinarof Cream	0.02 degrees C (±0.437 Standard Deviation)
NCT05142774	Dermatitis, Atopic	Complete Disease Clearance During LTE: Number of Subjects Achieving Disease Clearance vIGA-AD =0 (Clear) While on Therapy for Subjects Entered LTE vIGA-AD ≥ 1 (Almost Clear ) Baseline to Week 48	Tapinarof Cream	320 Participants
NCT05142774	Dermatitis, Atopic	Frequency of Adverse Events and Serious Adverse Events Baseline to Week 49	Tapinarof Cream	1226 Events
NCT05142774	Dermatitis, Atopic		Tapinarof Cream	45 Events
NCT05142774	Dermatitis, Atopic	Mean Change From Baseline in Eczema Area and Severity Index (EASI) Score Baseline to Week 48	Tapinarof Cream	-4.19 Units on a scale (±7.248 Standard Deviation)
NCT05142774	Dermatitis, Atopic	Mean Change in Peak Pruritis-Numeric Rating Scale (PP-NRS) From Baseline Baseline to Week 48	Tapinarof Cream	-1.618 Units on a scale (±2.7756 Standard Deviation)
NCT05142774	Dermatitis, Atopic	Number of Subjects With a Baseline Peak Pruritis-Numeric Rating Scale (PP-NRS) Score ≥ 4 Who Achieve ≥ 4-point Reduction in the PP-NRS From Baseline Baseline to Week 48	Tapinarof Cream	94 Participants
NCT05142774	Dermatitis, Atopic	Number of Subjects With Treatment-Emergent Adverse Events (TEAE) and Serious Adverse Events Baseline to Week 49	Tapinarof Cream	451 Participants
NCT05142774	Dermatitis, Atopic		Tapinarof Cream	34 Participants
NCT05142774	Dermatitis, Atopic	Percent Change From Baseline in %BSA Affected Baseline to Week 48	Tapinarof Cream	-37.45 percent change from baseline in % total (±189.905 Standard Deviation)
NCT05142774	Dermatitis, Atopic	Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score Baseline to Week 48	Tapinarof Cream	-33.70 Units on a scale (±139.557 Standard Deviation)
NCT05142774	Dermatitis, Atopic	Percent of Subjects With ≥ 50% Improvement in Eczema Area and Severity Index (EASI) From Baseline at Week 48. Baseline to Week 48	Tapinarof Cream	325 Participants
NCT05142774	Dermatitis, Atopic	Percent of Subjects With ≥ 75% Improvement in Eczema Area and Severity Index (EASI) From Baseline at Week 48. Baseline to Week 48	Tapinarof Cream	256 Participants
NCT05142774	Dermatitis, Atopic	Percent of Subjects With ≥ 90% Improvement in Eczema Area and Severity Index (EASI) From Baseline at Week 48. Baseline to Week 48	Tapinarof Cream	178 Participants
NCT05142774	Dermatitis, Atopic	Response During LTE: Number of Subjects Achieving vIGA-AD =0 or 1 (Clear or Almost Clear) While on Therapy for Subjects Who Entered LTE With vIGA-AD ≥ 2 (Mild) Baseline to Week 48	Tapinarof Cream	347 Participants

Publications by year

1998–2025: 25 publications.

1998

2001

2003

2005

2007

2008

2016

2017

2019

2020

2021

2022

2023

2024

2025

Publications by indication

Dermatitis, Atopic (17)

Tapinarof Improved Outcomes and Sleep for Patients and Families in Two Phase 3 Atopic Dermatitis Trials in Adults and Children.
Dermatol Ther (Heidelb) · 2025 · PMID 39777610 · NCT05014568
Maximal Usage Trial of Tapinarof Cream 1% Once Daily in Pediatric Patients Down to 2 Years of Age with Extensive Atopic Dermatitis.
Am J Clin Dermatol · 2025 · PMID 40126804 · NCT05186805
Tapinarof cream 1% once daily was well tolerated in adults and children with atopic dermatitis in two phase 3 randomized trials.
J Dermatolog Treat · 2025 · PMID 39799945 · NCT05032859
Characteristics and management of follicular events and contact dermatitis in patients using tapinarof cream for the treatment of atopic dermatitis or plaque psoriasis.
J Dermatolog Treat · 2025 · PMID 40600584 · NCT05014568
Tapinarof Cream for Adults and Children with Atopic Dermatitis-Efficacy by Race and Fitzpatrick Skin Type in Two Phase 3 Randomized Clinical Trials.
Dermatol Ther (Heidelb) · 2025 · PMID 40696240 · NCT05014568

Psoriasis (7)

Rapid Improvements in Itch with Tapinarof Cream 1% Once Daily in Two Phase 3 Trials in Adults with Mild to Severe Plaque Psoriasis.
Dermatol Ther (Heidelb) · 2024 · PMID 38123875 · NCT03983980
Tapinarof Cream 1% Once Daily for the Treatment of Plaque Psoriasis: Case Photography of Clinical Outcomes from Three Phase 3 Trials.
Dermatol Ther (Heidelb) · 2024 · PMID 37697121 · NCT03983980
First-in-Human Intrathoracic Implantation of Multidrug-Eluting Microdevices for In Situ Chemotherapeutic Sensitivity Testing as Proof of Concept in Nonsmall Cell Lung Cancer.
Ann Surg · 2023 · PMID 35129472 · NCT07352566
Intratumoral drug-releasing microdevices allow in situ high-throughput pharmaco phenotyping in patients with gliomas.
Sci Transl Med · 2023 · PMID 37672566 · NCT07352566
A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs.
Nat Biotechnol · 2022 · PMID 35788566 · NCT07352566

Publications by journal

Dermatol Ther (Heidelb)4 papers
J Invest Dermatol3 papers
J Am Acad Dermatol2 papers
N Engl J Med2 papers
Am J Clin Dermatol2 papers
J Dermatolog Treat2 papers
Sci Transl Med2 papers
Birth Defects Res B Dev Reprod Toxicol1 paper
Ann Surg1 paper
Nat Biotechnol1 paper

Trial-results highlights

In two pivotal studies, Tapinarof was evaluated for the treatment of psoriasis. In NCT03956355, at week 12, 35.4 percentage of subjects in the Tapinarof (DMVT-505) arm achieved a Physician Global Assessment (PGA) score of clear (0) or almost clear (1) with a minimum 2-grade improvement from baseline. In the same study, the vehicle cream arm reported 6.0 percentage of subjects. Similarly, in NCT03983980, at week 12, 40.2 percentage of subjects in the Tapinarof (DMVT-505) Cream Group achieved this same PGA endpoint, compared to 6.3 percentage of subjects in the Vehicle Cream Group.

A long-term extension study, NCT04053387, further explored the effects of continuous or intermittent use of Tapinarof (DMVT-505) Cream. At 40 weeks, participants showed a mean change from baseline of -2.03 percentage of BSA affected. The study also reported improvements in disease impact on daily activities, with a mean change from baseline of -2.0 scores on the Dermatology Life Quality Index (DLQI). Additionally, the mean change from baseline in Psoriasis Area and Severity Index (PASI) score was -1.80 scores on a scale. During the long-term extension, 233 participants achieved complete disease clearance (PGA=0) while on therapy. The mean duration of a treatment course in this study was 172.9 days.

Regarding safety in NCT04053387, the continuous or intermittent use of Tapinarof (DMVT-505) Cream was associated with 21 serious adverse events and 1190 total adverse events over 44 weeks. All values presented are sourced from primary registry reporting, and individual published papers should be consulted for comprehensive clinical context and decision-making.

All Tapinarof publications (25)

2025 (6 papers)

Tapinarof Improved Outcomes and Sleep for Patients and Families in Two Phase 3 Atopic Dermatitis Trials in Adults and Children.
Simpson EL, Hebert AA, Browning J, et al. · Dermatol Ther (Heidelb) · 2025 · Derived
PubMed: PMID 39777610 · NCT05014568 · Dermatitis, Atopic
Maximal Usage Trial of Tapinarof Cream 1% Once Daily in Pediatric Patients Down to 2 Years of Age with Extensive Atopic Dermatitis.
Paller AS, Hebert AA, Gonzalez ME, et al. · Am J Clin Dermatol · 2025 · Derived
PubMed: PMID 40126804 · NCT05186805 · Dermatitis, Atopic
Tapinarof cream 1% once daily was well tolerated in adults and children with atopic dermatitis in two phase 3 randomized trials.
Gold LS, Del Rosso J, Ehst BD, et al. · J Dermatolog Treat · 2025 · Derived
PubMed: PMID 39799945 · NCT05032859 · Dermatitis, Atopic
Characteristics and management of follicular events and contact dermatitis in patients using tapinarof cream for the treatment of atopic dermatitis or plaque psoriasis.
Gold LS, Bruno MJ, Lewitt GM, et al. · J Dermatolog Treat · 2025 · Derived
PubMed: PMID 40600584 · NCT05014568 · Dermatitis, Atopic
Tapinarof Cream for Adults and Children with Atopic Dermatitis-Efficacy by Race and Fitzpatrick Skin Type in Two Phase 3 Randomized Clinical Trials.
Alexis AF, Kircik L, Chovatiya R, et al. · Dermatol Ther (Heidelb) · 2025 · Derived
PubMed: PMID 40696240 · NCT05014568 · Dermatitis, Atopic
Maximal Usage Trial: An Overview of the Design of Systemic Bioavailability Trial for Topical Dermatological Products.
Bashaw ED, Tran DC, Shukla CG, et al. · Ther Innov Regul Sci · 2025 · Background
PubMed: PMID 26634191 · NCT05186805 · Dermatitis, Atopic

2024 (3 papers)

Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials.
Silverberg JI, Eichenfield LF, Hebert AA, et al. · J Am Acad Dermatol · 2024 · Trial result
PubMed: PMID 38777187 · NCT05032859 · Dermatitis, Atopic
Rapid Improvements in Itch with Tapinarof Cream 1% Once Daily in Two Phase 3 Trials in Adults with Mild to Severe Plaque Psoriasis.
Kircik L, Zirwas M, Kwatra SG, et al. · Dermatol Ther (Heidelb) · 2024 · Derived
PubMed: PMID 38123875 · NCT03983980 · Psoriasis
Tapinarof Cream 1% Once Daily for the Treatment of Plaque Psoriasis: Case Photography of Clinical Outcomes from Three Phase 3 Trials.
Desai SR, Stein Gold L, Cameron MC, et al. · Dermatol Ther (Heidelb) · 2024 · Derived
PubMed: PMID 37697121 · NCT03983980 · Psoriasis

2023 (2 papers)

First-in-Human Intrathoracic Implantation of Multidrug-Eluting Microdevices for In Situ Chemotherapeutic Sensitivity Testing as Proof of Concept in Nonsmall Cell Lung Cancer.
Tsai LL, Phillips WW, Hung YP, et al. · Ann Surg · 2023 · Background
PubMed: PMID 35129472 · NCT07352566 · Psoriasis
Intratumoral drug-releasing microdevices allow in situ high-throughput pharmaco phenotyping in patients with gliomas.
Peruzzi P, Dominas C, Fell G, et al. · Sci Transl Med · 2023 · Background
PubMed: PMID 37672566 · NCT07352566 · Psoriasis

2022 (2 papers)

Tapinarof Cream 1% for Extensive Plaque Psoriasis: A Maximal Use Trial on Safety, Tolerability, and Pharmacokinetics.
Jett JE, McLaughlin M, Lee MS, et al. · Am J Clin Dermatol · 2022 · Trial result
PubMed: PMID 34713415 · NCT04042103
A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs.
Tatarova Z, Blumberg DC, Korkola JE, et al. · Nat Biotechnol · 2022 · Background
PubMed: PMID 35788566 · NCT07352566 · Psoriasis

2021 (1 paper)

Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis.
Lebwohl MG, Stein Gold L, Strober B, et al. · N Engl J Med · 2021 · Trial result
PubMed: PMID 34879448 · NCT03956355 · Psoriasis

2020 (1 paper)

Aryl Hydrocarbon Receptor in Atopic Dermatitis and Psoriasis.
Furue M, Hashimoto-Hachiya A, Tsuji G, et al. · Int J Mol Sci · 2020 · Background
PubMed: PMID 31683543 · NCT05186805 · Dermatitis, Atopic

2019 (1 paper)

A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis.
Peppers J, Paller AS, Maeda-Chubachi T, et al. · J Am Acad Dermatol · 2019 · Background
PubMed: PMID 30554600 · NCT05186805 · Dermatitis, Atopic

2017 (1 paper)

Tapinarof Is a Natural AhR Agonist that Resolves Skin Inflammation in Mice and Humans.
Smith SH, Jayawickreme C, Rickard DJ, et al. · J Invest Dermatol · 2017 · Background
PubMed: PMID 28595996 · NCT05186805 · Dermatitis, Atopic

2016 (1 paper)

An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors.
Jonas O, Landry HM, Fuller JE, et al. · Sci Transl Med · 2016 · Background
PubMed: PMID 25904741 · NCT07352566 · Psoriasis

2008 (2 papers)

Barrier function and water-holding and transport properties of infant stratum corneum are different from adult and continue to develop through the first year of life.
Nikolovski J, Stamatas GN, Kollias N, et al. · J Invest Dermatol · 2008 · Background
PubMed: PMID 18200056 · NCT05186805 · Dermatitis, Atopic
Atopic dermatitis.
Bieber T · N Engl J Med · 2008 · Background
PubMed: PMID 18385500 · NCT05186805 · Dermatitis, Atopic

2007 (1 paper)

Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema.
Lewis-Jones S · Int J Clin Pract · 2007 · Background
PubMed: PMID 16893440 · NCT05186805 · Dermatitis, Atopic

2005 (1 paper)

The burden of atopic dermatitis: impact on the patient, family, and society.
Carroll CL, Balkrishnan R, Feldman SR, et al. · Pediatr Dermatol · 2005 · Background
PubMed: PMID 15916563 · NCT05186805 · Dermatitis, Atopic

2003 (1 paper)

Species comparison of anatomical and functional renal development.
Zoetis T, Hurtt ME · Birth Defects Res B Dev Reprod Toxicol · 2003 · Background
PubMed: PMID 12866702 · NCT05186805 · Dermatitis, Atopic

2001 (1 paper)

The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group.
Hanifin JM, Thurston M, Omoto M, et al. · Exp Dermatol · 2001 · Background
PubMed: PMID 11168575 · NCT05186805 · Dermatitis, Atopic

1998 (1 paper)

Development of skin barrier function in premature infants.
Kalia YN, Nonato LB, Lund CH, et al. · J Invest Dermatol · 1998 · Background
PubMed: PMID 9699737 · NCT05186805 · Dermatitis, Atopic

Sources and methodology

Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
Data freshness: Tue, 26 May 2026 17:56:24 GMT.

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).